Non-alcoholic fatty liver disease and cardiovascular pathology: pathogenetic parallels
Background. Recent studies and guidelines recognize non-alcoholic fatty liver disease (NAFLD) as an interdisciplinary problem at the intersection of gastroenterology, cardiology and endocrinology. The increased interest in NAFLD in recent years, as the most common chronic disease, identifies this pa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2024-08-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/1270 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background. Recent studies and guidelines recognize non-alcoholic fatty liver disease (NAFLD) as an interdisciplinary problem at the intersection of gastroenterology, cardiology and endocrinology. The increased interest in NAFLD in recent years, as the most common chronic disease, identifies this pathology as a participant in the development and progression of cardiovascular diseases and type 2 diabetes mellitus. The studies carried out consistently reveal the complex mechanisms of mutual influence of vascular pathology and NAFLD, as well as carbohydrate and fat metabolism disorders.Objective. The review article examines the pathogenetic pathways of the influence of NAFLD on the development and progression of cardiovascular diseases depending on risk factors and comorbidity. A clear association of NAFLD with obesity, metabolic syndrome and type 2 diabetes, as well as with cardiovascular diseases has been shown, which emphasizes the interdependence of these comorbid conditions.Results. Analysis of the course of NAFLD identifies several pathogenetic mechanisms – shocks (shocks), closely associated with metabolic disorders that affect the development of a wide range of pathologies, cardiovascular and endocrine. The negative impact of NAFLD on the development, course and prognosis of chronic kidney disease, malignant neoplasms of a number of localizations, as well as cirrhosis and liver cancer has also been shown. However, there is evidence that control and pathogenetically based therapy of NAFLD with correction of metabolic and concomitant vascular disorders can positively affect the course of both the disease itself and comorbid conditions. The role of ursodeoxycholic acid (UDCA) drugs in the treatment of NAFLD and the impact of this therapy on the course of associated diseases and conditions are discussed. The presence of pleiotropic effects of UDCA was noted, primarily on hepatocytes with the implementation of antioxidant, cytoprotective and antifibrotic effects, as well as metabolic effects: hypolipidemic effect, reduction in the level of total cholesterol and low-density lipoproteins, and a positive effect of UDCA on glycemic parameters.Conclusion. The complex interdependent mechanisms of the development of NAFLD, vascular and endocrine pathologies require further study and clarification, including the development of new and evaluation of existing approaches to the management of patients with similar conditions and diseases, which include the use of ursodeoxycholic acid. |
|---|---|
| ISSN: | 1560-5175 2687-1181 |